We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Low Profile Stent Graft Aids Patients with Aortic Disease

By HospiMedica International staff writers
Posted on 11 Dec 2019
A new thoracic stent graft system enables minimally invasive repair of lesions of the descending thoracic aorta, including thoracic aortic aneurysm (TAA) and dissections.

The CryoLife (Kennesaw, GA, USA) E-nya thoracic stent graft system is designed to increase treatment options for patients with thoracic aortic disease. More...
The endovascular stent graft system offers both bare spring and covered proximal configurations with tip capture technology, enhancing the control and predictability of the minimally invasive procedure during deployment for optimal outcomes. The lower profile textile graft material is designed to provide both flexibility in conformance and long-term durability.

The E-nya thoracic stent graft system is provided with a novel delivery system that addresses the issue of high-deployment forces, one of the major challenges of delivering low-profile transcatheter aortic valve replacement (TAVR) devices. The squeeze-to-release mechanism gives physicians much more control when treating both simple and challenging anatomies. E-nya is designed to complement the E-vita OPEN PLUS hybrid stent graft system, as well as a line of custom-made devices providing clinicians with the complete portfolio of products.

“The E-nya system was designed to give physicians more options and control while treating both simple and challenging anatomies, and will be one of the most versatile grafts on the market,” said Pat Mackin, chairman, president, and CEO of CryoLife. “We are pleased to have received CE Mark for the E-nya thoracic stent graft system, further enhancing our position as the leader in the growing EU aortic repair market.”

TAA results from continuous dilation of the descending thoracic aorta as a result of the degradation of structural proteins such as collagen and elastin, which eventually leads to medial degeneration and weakening of the aortic wall. Subsequent dilatation results from hemodynamic forces on the arterial wall, as well as intrinsic changes in the composition of the arterial wall itself, which cause the diameter of the aorta to expand further and increase wall tension, thus creating a vicious cycle and eventual life-threatening rupture and hemorrhage, if not treated.

Related Links:
CryoLife


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.